3,3-Diphenylpentane skeleton as a steroid skeleton substitute: Novel inhibitors of human 5α-reductase 1
摘要:
We designed and synthesized novel type 1 5 alpha-reductase inhibitors by using 3,3-diphenylpentane skeleton as a substitute for the usual steroid skeleton. 4-(3-(4-(N-Methylacetamido)phenyl)pentan-3-yl)phenyl dibenzylcarbamate (11k) is a competitive 5 alpha-reductase inhibitor with the IC50 value of 0.84 mu M. (C) 2007 Elsevier Ltd. All rights reserved.
3,3-Diphenylpentane skeleton as a steroid skeleton substitute: Novel inhibitors of human 5α-reductase 1
摘要:
We designed and synthesized novel type 1 5 alpha-reductase inhibitors by using 3,3-diphenylpentane skeleton as a substitute for the usual steroid skeleton. 4-(3-(4-(N-Methylacetamido)phenyl)pentan-3-yl)phenyl dibenzylcarbamate (11k) is a competitive 5 alpha-reductase inhibitor with the IC50 value of 0.84 mu M. (C) 2007 Elsevier Ltd. All rights reserved.
Disclosed herein are methods of treatment and prevention of diseases and disorders related to estrogen receptors comprising administering novel di-aromatic compounds to patients in need thereof.
[EN] COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE AU NIVEAU DES RECEPTEURS D'OESTROGENES
申请人:ACADIA PHARM INC
公开号:WO2007056500A2
公开(公告)日:2007-05-18
[EN] Disclosed herein are novel di-aromatic compounds and methods for using various di- aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors. [FR] La présente invention concerne de nouveaux composés diaromatiques et des procédés destinés à une utilisation de divers composés diaromatiques en vue de traiter et de prévenir des pathologies et des troubles liés aux récepteurs d'oetrogènes.
[EN] COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS<br/>[FR] COMPOSÉS PRÉSENTANT UNE ACTIVITÉ AUX RÉCEPTEURS D'OETROGÈNE
申请人:ACADIA PHARM INC
公开号:WO2008033894A2
公开(公告)日:2008-03-20
[EN] Disclosed herein are methods of treating neuropathic pain, reducing inflammation, reducing IL-4 levels, and reducing IFN-? levels, using various di-aromatic compounds for use as estrogen receptors ß agonists. [FR] L'invention concerne des procédés de traitement de la douleur neuropathique, de diminution des inflammations, de réduction des niveaux de IL-4 et de réduction des niveaux de IFN-? au moyen de divers composés di-aromatiques utilisés en qualité d'agonistes ß de récepteurs d'oetrogène.